# Transcranial magnetic stimulation in cocaine use disorder and the risk of seizure: a review of the evidence

**Authors:** Caesar G. Imperio, Eric Parmon, Vaughn R. Steele, Derek Blevins, Rebecca Chalme, Jonathan M. Wai, Kathleen Brady, Markus Heilig, Colleen A. Hanlon, Frances R. Levin, Diana Martinez

PMC · DOI: 10.3389/fpsyt.2026.1748184 · Frontiers in Psychiatry · 2026-02-04

## TL;DR

This paper reviews the risk of seizures when using transcranial magnetic stimulation (TMS) for treating cocaine use disorder and suggests ways to reduce that risk.

## Contribution

The paper provides a risk assessment framework and mitigation strategies for seizure risks in TMS treatment for cocaine use disorder.

## Key findings

- Seizures are more likely linked to recent cocaine use than TMS treatment itself.
- High-dose cocaine use requiring urgent care is most associated with seizure risk.
- Adjusting TMS parameters and monitoring motor thresholds can help mitigate seizure risks.

## Abstract

Transcranial magnetic stimulation (TMS) has emerged as a promising intervention for cocaine use disorder (CUD). However, a key concern when employing TMS in CUD is the potential risk of seizures. Our goal was to assess seizure risk in individuals with CUD undergoing TMS and to propose parameters that could mitigate it. Our review of the literature indicated that seizures are primarily associated with high-dose cocaine use necessitating urgent medical care – and that the risk is likely low outside of this setting. Thus, to mitigate potential seizure risks during TMS sessions, we suggest an assessment of recent cocaine use and an evaluation for cocaine toxicity. Additionally, rechecking motor threshold levels during treatment with TMS is recommended, especially if patterns of cocaine use change. Previous studies of TMS in CUD reported on two seizures that were linked to recent cocaine use rather than proximity to TMS treatment itself. Future research should document the timing of cocaine use relative to TMS sessions to further ensure the safety of this therapeutic approach.

## Linked entities

- **Chemicals:** cocaine (PubChem CID 2826)

## Full-text entities

- **Diseases:** mental distress (MESH:D012128), hyperthermia (MESH:D005334), hypotension (MESH:D007022), sleepiness (MESH:D000077260), Seizure (MESH:D012640), ectopic beats (MESH:D018879), nausea (MESH:D009325), arrhythmias (MESH:D001145), tachycardia (MESH:D013610), respiratory failure (MESH:D012131), confusion (MESH:D003221), vertigo (MESH:D014717), paranoia (MESH:D010259), cyanosis (MESH:D003490), irritability (MESH:D001523), substance use (MESH:D019966), loss of consciousness (MESH:D014474), insomnia (MESH:D007319), DM (MESH:D009223), anxiety (MESH:D001007), cardiac arrest (MESH:D006323), craving (MESH:C564883), mydriasis (MESH:D015878), headache (MESH:D006261), migraine (MESH:D008881), incontinence (MESH:D014549), ventricular fibrillation (MESH:D014693), cocaine overdose (MESH:D062787), coma (MESH:D003128), hypomania (MESH:D000087122), areflexia (MESH:D000071699), impaired social and vocational functioning (OMIM:300082), aggression (MESH:D010554), paresthesia (MESH:D010292), loss of vital function (MESH:D006315), ischemic stroke (MESH:D002544), psychosis (MESH:D011618), agitation (MESH:D011595), event (MESH:D002318), CUD (MESH:D019970), irregular breathing (MESH:D008599), tachypnea (MESH:D059246), dizziness (MESH:D004244), toxicity (MESH:D064420), hallucinations (MESH:D006212), intracerebral or subarachnoid hemorrhage (MESH:D013345), tremor (MESH:D014202), apnea (MESH:D001049), hypertension (MESH:D006973), encephalopathy (MESH:D001927), TMS (MESH:D007037)
- **Chemicals:** glutamate (MESH:D018698), GABA (MESH:D005680), methaqualone (MESH:D008702), amphetamines (MESH:D000662), alcohol (MESH:D000438), benzoylecgonine (MESH:C005618), LSD (MESH:D008238), PCP (MESH:D010622), Cocaine (MESH:D003042), heroin (MESH:D003932), methadone (MESH:D008691)
- **Species:** Nicotiana tabacum (American tobacco, species) [taxon 4097], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12913176/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12913176/full.md

## References

96 references — full list in the complete paper: https://tomesphere.com/paper/PMC12913176/full.md

---
Source: https://tomesphere.com/paper/PMC12913176